Author

Kim Wigglesworth

University of Massachusetts Chan Medical SchoolORCID 0009-0009-1215-7260Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Esteban J. RozeniD· 2 shared Jason Matthew ShohetiD· 2 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

2 top collaborators · 1 mutual co-author link

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Esteban J. RozenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyBiomedicinesPeer-reviewedJan 16, 2024

A novel druggable DYRK3/CAMKV signaling module for Neuroblastoma tumor growth inhibition.

Esteban J. Rozen, Kim Wigglesworth, Jason Matthew Shohet

This study identifies DYRK3 and CAMKV as a signaling module critical for neuroblastoma cell proliferation and tumor growth, suggesting their inhibition as a potential therapeutic strategy.

3 citations

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 4, 2023

Phosphorylation of MYCN and MAX by PAK family kinases is a novel tumor-suppressor mechanism in neuroblastoma with potential therapeutic implications.

Esteban J. Rozen, Kim Wigglesworth, Jason Matthew Shohet

The paper identifies PAK2-mediated phosphorylation of MYCN and MAX as a tumor-suppressor mechanism in neuroblastoma, with potential therapeutic strategies to restore its activity.

DOI 10.1101/2023.12.04.570005

humanexperimental assay

𝕏 PostBluesky